HAIXI PHARMA(02637),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02637 HAIXI PHARMA

Trading 04-14 15:41:06

182.400

-1.600

-0.87%

High187.700	Low175.200	Vol232.15K
Open184.300	D1 Closing184.000	Amplitude6.79%
Mkt Cap14.36B	Tradable Cap14.36B	Total Shares78.71M
T/O42.14M	T/O Rate0.29%	Tradable Shares78.71M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02637","market":"HK","secType":"STK","nameCN":"HAIXI PHARMA","latestPrice":182.4,"timestamp":1776152457457,"preClose":184,"halted":0,"volume":232150,"delay":0,"changeRate":-0.008695652173913012,"floatShares":78707270,"shares":78707270,"eps":2.9319166771120577,"marketStatus":"Trading","change":-1.6,"latestTime":"04-14 15:41:06","open":184.3,"high":187.7,"low":175.2,"amount":42141107,"amplitude":0.067935,"askPrice":182.4,"askSize":150,"bidPrice":180.7,"bidSize":1650,"shortable":0,"etf":0,"ttmEps":2.86293040235648,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1776154200000},"marketStatusCode":2,"adr":0,"listingDate":1760889600000,"exchange":"SEHK","adjPreClose":184,"openAndCloseTimeList":[[1776130200000,1776139200000],[1776142800000,1776153600000]],"volumeRatio":0.404262,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02637","defaultTab":"news","newsList":[{"id":"1112407237","title":"HAIXI PHARMA Maintains 78.71 Million Issued Shares in March 2026; Public Float Meets 25% Threshold","url":"https://stock-news.laohu8.com/highlight/detail?id=1112407237","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112407237?lang=en_us&edition=fundamental","pubTime":"2026-04-08 17:04","pubTimestamp":1775639074,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals Co., Ltd. (HAIXI PHARMA) filed its Monthly Return to Hong Kong Exchanges and Clearing for the period ended 31 March 2026, confirming no changes in either authorised or...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624828520","title":"Three Undiscovered Asian Gems To Enhance Your Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2624828520","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624828520?lang=en_us&edition=fundamental","pubTime":"2026-04-02 12:03","pubTimestamp":1775102626,"startTime":"0","endTime":"0","summary":"As geopolitical tensions and energy price volatility ripple through global markets, Asian equities are navigating a complex landscape with both challenges and opportunities. Amidst this backdrop, the S&P MidCap 400 and Russell 2000 indexes have shown resilience, highlighting the potential for small-cap stocks to thrive in uncertain times. In such an environment, identifying strong fundamentals and growth potential can be key to uncovering undiscovered gems that might enhance a diversified...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2637/fujian-haixi-pharmaceuticals-shares/news/three-undiscovered-asian-gems-to-enhance-your-portfolio","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2637/fujian-haixi-pharmaceuticals-shares/news/three-undiscovered-asian-gems-to-enhance-your-portfolio","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108606328","title":"HAIXI PHARMA Shares Surge Over 8% Following Strong FY2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1108606328","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108606328?lang=en_us&edition=fundamental","pubTime":"2026-04-01 10:20","pubTimestamp":1775010018,"startTime":"0","endTime":"0","summary":"HAIXI PHARMA (02637) saw its shares rise more than 8% after the company reported its financial results for the fiscal year 2025. As of the latest update, the stock was up 8.06%, trading at HK$172.9,...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637","BK4588","BK1191","VXUS","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100804736","title":"HAIXI PHARMA Reports 2025 Financial Results with Net Profit Jumping 30.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=1100804736","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100804736?lang=en_us&edition=fundamental","pubTime":"2026-03-31 00:20","pubTimestamp":1774887615,"startTime":"0","endTime":"0","summary":"HAIXI PHARMA (02637) has announced its financial results for 2025. The company reported revenue of approximately 582 million yuan, representing a year-on-year increase of 24.79%. Net profit reached...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184521353","title":"Haixi Pharma posts 30% profit jump in 2025, buoyed by generic drug sales and IPO proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=1184521353","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184521353?lang=en_us&edition=fundamental","pubTime":"2026-03-30 22:43","pubTimestamp":1774881832,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals (Haixi Pharma) reported solid full-year results for 2025, underpinned by robust growth in its generic drug portfolio and strengthened by fresh capital from its October...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148445511","title":"HAIXI PHARMA Shares Surge Over 4% in Morning Session as HXP056 Completes Phase I Enrollment and Initiates Phase II Study","url":"https://stock-news.laohu8.com/highlight/detail?id=1148445511","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148445511?lang=en_us&edition=fundamental","pubTime":"2026-03-25 10:38","pubTimestamp":1774406316,"startTime":"0","endTime":"0","summary":"HAIXI PHARMA (02637) saw its shares rise more than 4% during the morning trading session. At the time of writing, the stock was up 3.42%, trading at HKD 148, with a turnover of HKD 19.4604 million....","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637","BK1191","BK4585","BK4588","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193673628","title":"Haixi Pharma completes Phase I enrollment for first-in-class oral wAMD drug HXP056; Phase II study underway","url":"https://stock-news.laohu8.com/highlight/detail?id=1193673628","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193673628?lang=en_us&edition=fundamental","pubTime":"2026-03-24 17:21","pubTimestamp":1774344070,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals Co., Ltd. (Haixi Pharma) announced the full enrollment of patients into both the single ascending dose and multiple ascending dose cohorts of its Phase I clinical trial...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187639991","title":"HAIXI PHARMA's Oral wAMD Drug Candidate HXP056 Concludes Phase I Enrollment and Advances to Phase II","url":"https://stock-news.laohu8.com/highlight/detail?id=1187639991","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187639991?lang=en_us&edition=fundamental","pubTime":"2026-03-24 17:16","pubTimestamp":1774343796,"startTime":"0","endTime":"0","summary":"HAIXI PHARMA (02637) announced that its innovative drug candidate HXP056, a potential first-in-class oral medication for hemorrhagic retinal diseases, has completed patient enrollment for the Phase I...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621605091","title":"Fujian Haixi Pharma starts Phase 2 China trial of HXP056 for wet age-related macular degeneration","url":"https://stock-news.laohu8.com/highlight/detail?id=2621605091","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621605091?lang=en_us&edition=fundamental","pubTime":"2026-03-24 17:11","pubTimestamp":1774343471,"startTime":"0","endTime":"0","summary":"Haixi Pharmaceuticals said its oral wet age-related macular degeneration  candidate HXP056 has completed Phase 1 patient enrollment and has moved into a Phase 2 dose-expansion study in China.The company is positioning HXP056 as an oral alternative in retinal disease indications, which could broaden treatment access compared with injection-based care if later-stage trials support approval.Haixi Pharmaceuticals said the program is designed to support drug distribution to the retina, aiming to reduce development constraints that have limited oral approaches in this area.The company plans to use Phase 2 results to select an optimal dose to support a future Phase 3 study.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fujian Haixi Pharmaceu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL1N0ttT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148839371","title":"HAIXI PHARMA (02637) Sets 30 Mar 2026 Board Meeting to Approve FY 2025 Results and Consider Final Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=1148839371","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148839371?lang=en_us&edition=fundamental","pubTime":"2026-03-10 16:44","pubTimestamp":1773132298,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals Co., Ltd. (HAIXI PHARMA, 02637) has scheduled a board meeting for Monday, 30 March 2026. The agenda includes: • Reviewing and approving the Group’s consolidated results...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175166735","title":"HAIXI PHARMA (02637) Announces Appointment of Liu Guoxian as Joint Company Secretary, Authorized Representative, and Legal Process Agent","url":"https://stock-news.laohu8.com/highlight/detail?id=1175166735","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175166735?lang=en_us&edition=fundamental","pubTime":"2026-03-06 16:43","pubTimestamp":1772786581,"startTime":"0","endTime":"0","summary":"HAIXI PHARMA (02637) announced that Ms. Lin Huiyi has resigned from her positions as the company's Joint Company Secretary; the authorized representative of the company as stipulated under Rule 3.05...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617683673","title":"Fujian Haixi Pharmaceuticals appoints Lau Kwok Yin as joint company secretary","url":"https://stock-news.laohu8.com/highlight/detail?id=2617683673","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617683673?lang=en_us&edition=fundamental","pubTime":"2026-03-06 16:36","pubTimestamp":1772786187,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals Co. Ltd. said Sophie Lam Wai Yee has resigned as joint company secretary, authorised representative and process agent, effective 6 March 2026. The company appointed Lau Kwok Yin as joint company secretary, authorised representative and process agent from 6 March 2026. Lau is a vice president in the Listed Corporate Secretarial Department at SWCS Corporate Services Group  and has over 15 years of experience in corporate secretarial services, finance and banking operations. Zhang Junhuan will remain as joint company secretary.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fujian Haixi Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Serv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nNDL5CfzpH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168367303","title":"HAIXI PHARMA (02637) Announces February 2026 Monthly Return on Share Movements","url":"https://stock-news.laohu8.com/highlight/detail?id=1168367303","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168367303?lang=en_us&edition=fundamental","pubTime":"2026-03-05 17:26","pubTimestamp":1772702807,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals Co., Ltd. (stock code: 02637) published its monthly return on movements in securities for the period ended 28 February 2026. The announcement indicates that the total...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145194990","title":"Fujian Haixi Pharmaceuticals (2637) Announces New Senior Management Appointment","url":"https://stock-news.laohu8.com/highlight/detail?id=1145194990","media":"Bulletin Express","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145194990?lang=en_us&edition=fundamental","pubTime":"2026-03-01 18:25","pubTimestamp":1772360748,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals Co., Ltd. (Stock Code: 2637) announced the appointment of Dr. Zhang Mingqiang as President of Research & Development and Global Affairs, effective March 1, 2026. Dr....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616821844","title":"Fujian Haixi Pharmaceuticals Appoints Zhang Mingqiang as President of R&D and Global Affairs","url":"https://stock-news.laohu8.com/highlight/detail?id=2616821844","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616821844?lang=en_us&edition=fundamental","pubTime":"2026-03-01 18:09","pubTimestamp":1772359768,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals Co. Ltd. has appointed Dr. Zhang Mingqiang as President of Research and Development and Global Affairs, effective 1 March 2026. Zhang previously held senior R&D leadership roles at Amgen, Merck Sharp and Dohme, Roche, and Biotica Technology.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fujian Haixi Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 01, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260301:nNDL2kBCFp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1162221912.USD","IE0009355771.USD","LU2125154935.USD","SG9999014559.SGD","LU0106261372.USD","SG9999001440.SGD","LU0122379950.USD","LU0265550359.USD","BK4588","LU0266013472.USD","LU0980610538.SGD","LU1116320901.HKD","LU1066051225.USD","LU0234572021.USD","SG9999001176.USD","SG9999013999.USD","LU1941712264.USD","LU0211331839.USD","LU1941712348.USD","LU0265550946.USD","LU0432979614.USD","LU1057294990.SGD","LU1069347547.HKD","LU2361044865.SGD","LU0320765489.SGD","LU1989771016.USD","BK1191","LU2106854487.HKD","LU1066051811.HKD","IE00BSNM7G36.USD","LU2461242641.AUD","LU1974910355.USD","BK4533","IE00BBT3K403.USD","LU2468319806.SGD","BK4007","LU0965509283.SGD","LU2023250504.SGD","SG9999015358.SGD","SG9999014567.USD","BK4559","LU1585245621.USD","LU0130517989.USD","SGXZ57979304.SGD","LU1116320737.USD","LU0208291251.USD","LU1989772923.USD","LU0098860793.USD","IE00BN8TJ469.HKD","LU2089984988.USD","LU1934455277.USD","LU0477156953.USD","LU1291159041.SGD","LU1023059063.AUD","LU1201861249.SGD","IE0002141913.USD","BK4534","IE00BFTCPJ56.SGD","02637","IE000M9KFDE8.USD","SG9999002232.USD","LU1037948541.HKD","SG9999001176.SGD","IE00BJJMRZ35.SGD","IE00BLSP4239.USD","LU1929549753.HKD","SG9999014542.SGD","IE00B4R5TH58.HKD","LU0006306889.USD","LU0861579265.USD","LU1699723380.USD","IE00BLSP4452.SGD","LU1035773651.USD","LU0965509101.SGD","LU0203345920.USD","IE00B2B36J28.USD","LU0070302665.USD","LU2360032135.SGD","LU0965509010.AUD","SG9999015341.SGD","LU1934455194.USD","LU1037948897.HKD","LU2112291526.USD","SG9999002224.SGD","IE00B1BXHZ80.USD","LU2324357040.USD","BK4550","LU1066053197.SGD","LU2125154778.USD","LU2023250843.SGD","LU2361045086.USD","LU0985320562.USD","BK4585","LU1061106388.HKD","BK4516","LU1983299246.USD","LU1917777945.USD","LU1934455863.HKD","LU0289739699.SGD","SG9999014575.USD","IE00BJT1NW94.SGD","LU0058720904.USD","LU0965508806.USD","LU1093756168.USD","LU2361044949.HKD","LU0130102774.USD","LU1571399168.USD","LU1430594728.SGD","LU0320765646.SGD","LU1989772840.SGD","LU0238689110.USD","LU1066051498.USD","LU1093756325.SGD","LU0203347892.USD","LU0648001328.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109472366","title":"Fujian Haixi (02637) Releases January 2026 Monthly Return with No Changes in Issued Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1109472366","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109472366?lang=en_us&edition=fundamental","pubTime":"2026-02-05 17:05","pubTimestamp":1770282308,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals Co., Ltd. (stock code: 02637) released its monthly return for the period ended January 31, 2026. According to the announcement, the total authorized share capital...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158233492","title":"Fujian Haixi Pharmaceuticals (2637) Announces HKD200 Million Fund Linked Notes Subscription and Up to HKD200 Million Investment in China Rock Fund SPC","url":"https://stock-news.laohu8.com/highlight/detail?id=1158233492","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158233492?lang=en_us&edition=fundamental","pubTime":"2026-02-05 16:46","pubTimestamp":1770281219,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals Co., Ltd. (Stock Code: 2637) announced that on 24 October 2025, it subscribed for HKD200 million in Series 2025-32 Fund Linked Notes issued by Essence Global Investment...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136379883","title":"HAIXI PHARMA Allocates Idle Capital to Financial Products","url":"https://stock-news.laohu8.com/highlight/detail?id=1136379883","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136379883?lang=en_us&edition=fundamental","pubTime":"2026-02-05 16:40","pubTimestamp":1770280827,"startTime":"0","endTime":"0","summary":"HAIXI PHARMA (02637) has announced that on October 24, 2025, Fujian Haixi New Drug Creation Co., Ltd., acting as an investor, utilized its idle funds to subscribe to (i) HKD 200 million worth of...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637","BK1191","159940"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152094182","title":"Zhixiong Hong Kong Stock 52-Week Highs and Lows Statistics | January 16","url":"https://stock-news.laohu8.com/highlight/detail?id=1152094182","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152094182?lang=en_us&edition=fundamental","pubTime":"2026-01-16 16:55","pubTimestamp":1768553758,"startTime":"0","endTime":"0","summary":"As of the market close on January 16, a total of 123 stocks reached new 52-week highs. Among them, Skymission Group (01429), Weigong Holdings (01793), and Kin Shing Holdings (01630) recorded the highest percentage gains, at 103.39%, 43.17%, and 35.59% respectively.","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1169","LU2088748293.HKD","BK1116","SG9999002463.SGD","HK0000500386.USD","LU0287142896.SGD","IE0008369823.USD","BK1099","03393","LU0082770016.USD","LU0449509016.USD","IE00BVYPNQ40.USD","BK1507","08310","LU0348783233.USD","LU0359201612.USD","LU2226123490.SGD","IE00B1G9TM23.USD","SG9999010078.USD","LU0417516571.SGD","02605","00842","LU0149534421.HKD","BK1151","LU0229494975.USD","01903","BK1130","BK1559","BK1544","LU0516422952.EUR","BK1541","LU0164939612.USD","BK1162","00065","LU0620787316.HKD","00386","00002","BK1249","LU0828237940.HKD","BK1206","BK1521","LU0702159343.USD","LU1282651048.USD","01851","BK1555","LU2039709279.SGD","00695","LU0370786039.SGD","BK1502","00631","01972","LU1282649810.SGD","LU1188198961.HKD","BK1527","LU1211504680.USD","02631","BK1157","01205","03993","LU0405327148.USD","BK1137","BK1188","00358","LU1880383366.USD","BK1205","LU0173614495.USD","LU0898667661.SGD","08621","LU2226123227.USD","BK1610","LU0384037296.USD","LU1481107354.HKD","BK1225","LU1634259557.SGD","BK1110","BK1601","08257","LU1048596156.SGD","BK1179","01201","LU0540923850.HKD","00017","LU0516422366.SGD","LU1044875133.USD","BK1228","LU0823426308.USD","00014","LU0955648018.USD","BK1213","BK1534","LU0463099449.HKD","IE00BVYPNP33.GBP","BK1124","LU0164880469.USD","LU2213484517.USD","BK1522","02788","01347","LU1497734951.SGD","BK1190","LU1497733631.SGD","BK1595","01630","BK1163","BK1512","LU1634259391.SGD","BK1227","00001","SG9999014674.SGD","LU1831875114.USD","LU0572939691.SGD","01196","02655","BK1178","LU1102505762.USD","BK1122","03132","BK1224","02521","LU0541501648.USD","02680","LU0293314216.USD","LU0264606111.USD","BK1568","BK1258","00340","BK1230","LU1282649141.HKD","BK1572","03858","BK1148","BK1240","BK1229","02259","BK1583","BK1577","IE0032431581.USD","LU0140636845.USD","LU1515016050.SGD","LU2125910500.SGD","LU2088748376.SGD","02025","BK1113","BK1513","BK1170","LU0405327494.USD","02516","SG9999003461.SGD","LNNGY","LU0955669360.SGD","02331","LU0054450605.USD","06600","LU2097828714.EUR","LU1051769294.HKD","00590","01408","BK1602","LU0348805143.USD","BK1560","BK1506","BK1198","03317","LU0648948544.HKD","01866","BK1614","SGXZ86797644.SGD","LU1316543674.SGD","09696","00005","LU0651947912.USD","02651","LU0593848301.USD","LU1571399168.USD","LU0449515922.USD","01300","02685","01637","LU0205439572.USD","BK1175","BK1500","LU0149721374.USD","LU0516423091.SGD","HSHD.SI","01481","LU0052750758.USD","BK1216","BK1528","SG9999010052.SGD","BK1592","IE00BSPPW651.USD","BK1587","HSBC","LU0417516738.SGD","LU0708995583.HKD","LU1522347837.USD","00262","LU0348735423.USD","02661","LU2045819591.USD","BK1117","02588","LU1051768304.USD","01113","BK1106","BK1543","00162","LU0488056044.USD","02350","LU0072462343.USD","LU0320764599.SGD","LU0082770016.SGD","LU0348784397.USD","LU0821914370.USD","01580","BK1589","LU1044876610.USD","BK1239","LU1023057109.AUD","SG9999002950.SGD","BK1171","LU0877626530.USD","08418","LU0181495838.USD","LU0737861699.HKD","IE00BG0RBZ43.SGD","LU1130305938.SGD","LU1880383440.USD","LU1166156734.SGD","LU0738912210.USD","00826","BK1147","HSBA.UK","LU1282649067.USD","LU2348773727.SGD","BK1135","01793","03145","LU0214875030.USD","LU0541502299.USD","LU0359202008.SGD","LU0651946864.USD","02285","03121","LU0516423174.USD","02002","02513","LU0228367735.SGD","LU0831093199.SGD","BK1129","LU2088747998.USD","LU0359201885.HKD","00086","02637","BHKLY","03165","01772","BK1556","LU0315179316.USD","01979","BK1143","LU1119993845.HKD","BK1545","BK1231","03986","03899","BK1533","BK1144","HK0000252160.HKD","02338","82331","LU0244354667.USD","LU2153591404.USD","BK1562","LU1048588211.SGD","BK1569","LU2097828557.USD","BK1183","LU0762540952.USD","00083","SG9999006597.SGD","LU2543165471.USD","LU0414403682.SGD","BK1514","LU0831103253.SGD","BK1210","LU2097828474.EUR","00659","02381","IE00BHRH8C09.USD","LU2097828631.EUR","00876","IE0034224299.USD","BK1551","09983","BK1149","01133","LU2088748020.USD","02671","BK1542","BK1509","02635","LU0163747925.USD","SG9999004220.SGD","LU1328615791.USD","LU1044874839.SGD","LU2242644610.SGD","BK1191","00180","BK1505","BK1140","80016","HK0000252152.HKD","LU0516422440.USD","01429","LU0572940350.SGD","LU1808992512.USD","00368","BK1540","LU2097828805.USD","02099","02198","SG9999009997.SGD","09982","BK1546","03330","LU0955623706.USD","SGXZ62798434.SGD","02650","00440","02610","06651","LU0326950275.SGD","BK1222","02276","LU0634319403.HKD","BK1226","LU0702159699.USD","82388","03143","LU0327786744.USD","BK1607","LU0607220059.USD","LU1224709979.USD","SUHJY","LU0048580855.USD","03431","LU1642822792.SGD","BK1548","LU2088747725.USD","08087","BK1594","08072","LU1102505929.USD","IE00BGHQDM52.EUR","00016","BK1214","03483","01233","IE00B1G9TL16.USD","LU1497733557.USD","02388","LU0572944931.SGD","LU0823426480.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197239226","title":"Zhitieng Hong Kong Stocks 52-Week Highs and Lows Statistics | January 14","url":"https://stock-news.laohu8.com/highlight/detail?id=1197239226","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197239226?lang=en_us&edition=fundamental","pubTime":"2026-01-14 16:50","pubTimestamp":1768380643,"startTime":"0","endTime":"0","summary":"As of the market close on January 14, a total of 113 stocks reached new 52-week highs. The top three stocks with the highest percentage gains were Feidao Travel Technology (08069), Gracewine (08146),...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1164","02338","08069","BK1225","00086","03939","08418","00358","BK1544","LU0405327148.USD","HK0000306685.HKD","03882","00631","BK1099","LU1497733631.SGD","BK1148","BK1610","BK1563","02166","00002","LU0634319403.HKD","LU0871576103.HKD","LU0228659784.USD","03317","HK0000306701.USD","BK1137","BK1220","02680","02889","BK1617","LU1571399168.USD","BK1568","BK1129","LU0345780281.USD","LU1794554557.SGD","LU0096374516.USD","LU0328353924.USD","08403","LU0049853897.USD","SGXZ62798434.SGD","00661","03199","SG9999003461.SGD","BK1589","HK0000288784.HKD","09638","LU1634259557.SGD","BK1601","01772","LU0702159343.USD","BK1254","LU0737861772.HKD","LU0164865239.USD","LU1720050803.USD","LU0164939612.USD","LU0384037296.USD","BK1206","BK1548","BK1157","LU0877626530.USD","BK1179","LU0082770016.USD","BK1502","LU0417516902.SGD","09956","LU0469268626.HKD","01540","IE00BG0RBZ43.SGD","LU0831103253.SGD","LU1211504680.USD","BK1584","00026","LU0266512127.USD","BK1210","LU2097828714.EUR","00001","02352","LU0463099449.HKD","LU0561508036.HKD","03330","LU0173614495.USD","01669","00339","BK1156","01832","BK1198","IE0034224299.USD","BK1591","LU0048580855.USD","01104","LU1282649810.SGD","BK1147","BK1501","BK1587","LU2039709279.SGD","LU0326950275.SGD","LU1522347837.USD","BK1509","BK1239","BK1222","BK1188","02009","00129","LU1719994722.HKD","00373","BK1258","01138","BK1551","LU0572944931.SGD","BK1535","BK1583","BK1160","BK1149","LU0593848301.USD","LU1481107354.HKD","BK1128","HK0000320223.HKD","01300","01757","BK1116","LU0039217434.USD","LU1251922891.USD","LU0327786744.USD","LU1048596156.SGD","BK1569","LU1504937902.USD","03393","LU1770034418.SGD","01091","LU0072462343.USD","LU2399975544.HKD","BK1189","01818","BK1614","BK1142","02425","BK1552","LU1242518857.USD","01977","LU1166156734.SGD","SG9999002950.SGD","LU0828237510.HKD","03160","00842","02227","03311","LU0106252389.USD","LU1634259391.SGD","06618","LU1303224171.USD","BK1522","LU0762540952.USD","86618","02635","LU0620787316.HKD","BK1192","LU0345780521.USD","BK1592","02689","HK0000252160.HKD","BK1096","09982","SG9999002463.SGD","00241","LU0329678337.USD","BK1124","02482","08072","LU0828237940.HKD","BK1500","LU2213484517.USD","HK0000288743.USD","00826","LU0405327494.USD","SG9999006597.SGD","08321","BK1503","LU0370786039.SGD","LU1831875114.USD","03878","BK1615","BK1521","LU2543165471.USD","02685","BK1190","00111","BK1247","LU0456827905.SGD","03076","LU1808992512.USD","02442","01208","LU0821914370.USD","BK1162","LU0702159699.USD","LU1119993845.HKD","01380","BK1144","BK1505","LU1769817096.USD","BK1135","BK1237","00970","02551","LU0082770016.SGD","00659","BK1171","HK0000320264.USD","01481","HK0000500386.USD","BK1577","03145","BK1166","08146","LU0205439572.USD","LU1769817179.HKD","LU1048588211.SGD","02307","03858","LU0886674414.USD","BK1542","BK1213","BK1143","LU1242518931.SGD","LU0531971595.HKD","02231","02637","BK1515","SG9999004220.SGD","LU0588546209.SGD","LU0737861699.HKD","02099","00400","IE0008369823.USD","LU1497734951.SGD","BK1229","BK1216","08591","LU0164880469.USD","LU0979878070.USD","LU0140636845.USD","BK1215","LU0051755006.USD","BK1257","02588","06136","00994","BK1540","02515","HK0000252152.HKD","01580","LU0488056044.USD","00075","00876","LU2097828474.EUR","LU2097828557.USD","BK1506","LU0831093199.SGD","LU0181495838.USD","BK1240","BK1594","BK1507","LU0348825331.USD","LU0307460666.USD","02829","06651","LU0287142896.SGD","SGXZ86797644.SGD","03662","BK1527","LU2097828805.USD","LU1497733557.USD","BK1223","02002","LU0244354667.USD","BK1151","LU1224709979.USD","SG9999014674.SGD","IE0032431581.USD","BK1230","02661","08627","LU2097828631.EUR","08603","LU0061477393.USD","IE00BHRH8C09.USD","BK1218","LU0348827113.USD","BK1571","00089","BK1106","LU0898667661.SGD","BK1194","09936","02899","LU0348735423.USD","LU1188198961.HKD","LU1961090484.USD","LU0417516738.SGD","LU0456854461.SGD","02259","LU0266512473.USD","BK1181","LU0211977185.USD","LU0540923850.HKD","LU1282649067.USD","BK1513","BK1191","BK1514","LU0149721374.USD","01641","LU0329678170.USD","BK1249"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.hxpharma.com","stockEarnings":[{"period":"1week","weight":0.0413},{"period":"1month","weight":0.2374},{"period":"3month","weight":0.1818},{"period":"6month","weight":1.1296},{"period":"ytd","weight":0.3529}],"compareEarnings":[{"period":"1week","weight":0.0217},{"period":"1month","weight":0.0077},{"period":"3month","weight":-0.0442},{"period":"6month","weight":-0.0096},{"period":"1year","weight":0.2269},{"period":"ytd","weight":0.0012}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Fujian Haixi Innovative Drug Development Co., Ltd. was established on March 27, 2012. The company is a commercial-stage pharmaceutical firm that integrates R&D, manufacturing and sales capabilities, and maintains a pipeline of innovative drug candidates. It owns a diversified product portfolio and pipeline across China’s largest and fastest-growing therapeutic areas. As of the latest practicable date, its commercialized portfolio consists mainly of generics for digestive, cardiovascular, endocrine, neurological and inflammatory diseases. According to CIC, these therapeutic areas accounted for over 25 % of China’s total pharmaceutical sales in 2023. The company’s innovative pipeline focuses on drug candidates for multiple indications, including a potential first-in-class oncology asset, a potential first-in-class oral therapy for wet age-related macular degeneration (wAMD) / diabetic macular edema (DME) / retinal vein occlusion (RVO), and two additional pre-clinical-stage innovative programs for oncology and respiratory diseases. All innovative drug candidates are developed and advanced internally through proprietary technologies.","exchange":"SEHK","name":"HAIXI PHARMA","nameEN":"HAIXI PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"HAIXI PHARMA(02637),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest HAIXI PHARMA(02637) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"HAIXI PHARMA,02637,HAIXI PHARMA股票,HAIXI PHARMA股票老虎,HAIXI PHARMA股票老虎国际,HAIXI PHARMA行情,HAIXI PHARMA股票行情,HAIXI PHARMA股价,HAIXI PHARMA股市,HAIXI PHARMA股票价格,HAIXI PHARMA股票交易,HAIXI PHARMA股票购买,HAIXI PHARMA股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"HAIXI PHARMA(02637),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest HAIXI PHARMA(02637) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}